• Je něco špatně v tomto záznamu ?

Pancreatic islet autotransplantation after completion pancreatectomy for pancreatic fistula after hemipancreatoduodenectomy for carcinoma

M. Kocik, K. Lipar, F. Saudek, P. Girman, P. Boucek, M. Kucera, J. Fronek, M. Oliverius,

. 2014 ; 46 (6) : 1996-8.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15031901

OBJECTIVE: Pancreatic islet autotransplantation (IAT) has a potential to prevent brittle diabetes in patients after total pancreatectomy. Because of the fear of tumor spread, IAT has rarely been used in case of malignancy. We report our experience with patients who underwent hemipancreatoduodenectomy for carcinoma and later completion pancreatectomy for pancreatic fistula with islet autotransplantation at our institution. METHODS: From August 2007 to December 2012, 5 patients underwent IAT after completion pancreatectomy for pancreatic fistula after hemipancreatoduodenectomy for carcinoma. Islets were isolated from the pancreatic tail with the use of digestion with collagenase. Nonpurified islet suspension was infused into the portal vein during surgery. RESULTS: The median number of islets transplanted was 175,000 islet equivalents (range, 70,000-365,000). One patient died after surgery for reasons unrelated to IAT. Another 3 patients had stable diabetes with partial graft function (fasting C-peptide levels 0.23, 0.41, and 0.61 nmol/L and HbA1c 4.8%, 4.6%, and 6.9% at 24, 24 and 9 months after IAT, respectively). The 1st patient, with pancreatic head carcinoma, was alive 28 months after IAT with lymph node and liver recurrence since 18 months after IAT. The 2nd patient, with gall bladder and distal bile duct carcinoma, died 47 months after IAT with tumor recurrence. The 3rd patient, with ampullary carcinoma, died 12 months after IAT with local recurrence and solitary liver metastasis. The last patient had been off insulin 9 months after IAT without tumor recurrence (fasting C-peptide, 0.89 nmol/L; HbA1c, 4.2%). CONCLUSIONS: Autotransplantation of pancreatic islets isolated from the residual pancreatic tissue in patients who previously underwent hemipancreatoduodenectomy for cancer may provide stable glucose control and thus improve quality of life. In this small series we did not observe early development of multiple liver metastases caused by islet suspension contamination with malignant cells. Oncologic outcome of the patients was not worse than what would be expected without IAT.

000      
00000naa a2200000 a 4500
001      
bmc15031901
003      
CZ-PrNML
005      
20151014131550.0
007      
ta
008      
151005s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.transproceed.2014.06.009 $2 doi
035    __
$a (PubMed)25131092
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kocik, M $u Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address: matej.kocik@ikem.cz.
245    10
$a Pancreatic islet autotransplantation after completion pancreatectomy for pancreatic fistula after hemipancreatoduodenectomy for carcinoma / $c M. Kocik, K. Lipar, F. Saudek, P. Girman, P. Boucek, M. Kucera, J. Fronek, M. Oliverius,
520    9_
$a OBJECTIVE: Pancreatic islet autotransplantation (IAT) has a potential to prevent brittle diabetes in patients after total pancreatectomy. Because of the fear of tumor spread, IAT has rarely been used in case of malignancy. We report our experience with patients who underwent hemipancreatoduodenectomy for carcinoma and later completion pancreatectomy for pancreatic fistula with islet autotransplantation at our institution. METHODS: From August 2007 to December 2012, 5 patients underwent IAT after completion pancreatectomy for pancreatic fistula after hemipancreatoduodenectomy for carcinoma. Islets were isolated from the pancreatic tail with the use of digestion with collagenase. Nonpurified islet suspension was infused into the portal vein during surgery. RESULTS: The median number of islets transplanted was 175,000 islet equivalents (range, 70,000-365,000). One patient died after surgery for reasons unrelated to IAT. Another 3 patients had stable diabetes with partial graft function (fasting C-peptide levels 0.23, 0.41, and 0.61 nmol/L and HbA1c 4.8%, 4.6%, and 6.9% at 24, 24 and 9 months after IAT, respectively). The 1st patient, with pancreatic head carcinoma, was alive 28 months after IAT with lymph node and liver recurrence since 18 months after IAT. The 2nd patient, with gall bladder and distal bile duct carcinoma, died 47 months after IAT with tumor recurrence. The 3rd patient, with ampullary carcinoma, died 12 months after IAT with local recurrence and solitary liver metastasis. The last patient had been off insulin 9 months after IAT without tumor recurrence (fasting C-peptide, 0.89 nmol/L; HbA1c, 4.2%). CONCLUSIONS: Autotransplantation of pancreatic islets isolated from the residual pancreatic tissue in patients who previously underwent hemipancreatoduodenectomy for cancer may provide stable glucose control and thus improve quality of life. In this small series we did not observe early development of multiple liver metastases caused by islet suspension contamination with malignant cells. Oncologic outcome of the patients was not worse than what would be expected without IAT.
650    _2
$a karcinom $x mortalita $x patologie $x chirurgie $7 D002277
650    _2
$a kohortové studie $7 D015331
650    _2
$a diabetes mellitus 1. typu $x etiologie $x mortalita $x chirurgie $7 D003922
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a transplantace Langerhansových ostrůvků $7 D016381
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a pankreatektomie $x škodlivé účinky $7 D010180
650    _2
$a pankreatická píštěl $x etiologie $x mortalita $x chirurgie $7 D010185
650    _2
$a nádory slinivky břišní $x mortalita $x patologie $x chirurgie $7 D010190
650    _2
$a pankreatoduodenektomie $x škodlivé účinky $7 D016577
650    _2
$a autologní transplantace $7 D014182
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lipar, K $u Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Saudek, F $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Girman, P $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Boucek, P $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kucera, M $u Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Fronek, J $u Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Oliverius, M $u Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
773    0_
$w MED00004556 $t Transplantation proceedings $x 1873-2623 $g Roč. 46, č. 6 (2014), s. 1996-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25131092 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151014131740 $b ABA008
999    __
$a ok $b bmc $g 1092777 $s 915027
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 46 $c 6 $d 1996-8 $i 1873-2623 $m Transplantation proceedings $n Transplant Proc $x MED00004556
LZP    __
$a Pubmed-20151005

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...